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ABSTRACT: Simultaneous triggering of Toll-like receptors (TLRs) and NOD-
like receptors (NLRs) has previously been shown to synergistically activate
monocytes, dendritic cells, and macrophages. We applied these properties in a T-
cell vaccine setting by conjugating the NOD2-ligand muramyl-dipeptide (MDP)
and TLR2-ligand Pam3CSK4 to a synthetic peptide derived from a model antigen.
Stimulation of human DCs with the MDP-peptide-Pam3CSK4 conjugate led to a
strongly increased secretion of pro-inflammatory and Th1-type cytokines and
chemokines. We further show that the conjugated ligands retain their ability to
trigger their respective receptors, while even improving NOD2-triggering. Also,
activation of murine DCs was enhanced by the dual triggering, ultimately leading to
effective induction of vaccine-specific T cells expressing IFNγ, IL-2, and TNFα. Together, these data indicate that the dual
MDP-SLP-Pam3CSK4 conjugate constitutes a chemically well-defined vaccine approach that holds promise for the use in the
treatment of virus infections and cancer.
■ INTRODUCTION
During pathogenic infection, the innate immune system is
exposed to a diverse array of pathogen-associated molecular
patterns (PAMPs). Upon recognition of PAMPs by pathogen-
recognition receptors (PRRs) such as the Toll-like receptors
(TLR) and nucleotide-binding oligomerization domain
(NOD)-like receptors (NLR), downstream signaling can
generally lead to pro-inflammatory cytokine production by
antigen-presenting cells (APCs) and increased expression of
co-stimulatory proteins on their cell surface to optimize T cell
activation.1 The agonistic properties of TLR-ligands (TLR-L)
have gained widespread interest in vaccine research as they can
serve as immune-potentiating vaccine adjuvants.2−4 Our group
has shown that the potency of synthetic long peptide (SLP)
vaccination can be strongly enhanced by conjugating the SLPs
to TLR2-L Pam3CSK4 (Pam),
4 which effectuates the targeting
of SLPs to TLR2-expressing APCs while concomitantly
activating or maturing the APC.5
Muramyl-dipeptide (MDP), the minimal immune-stimula-
tory peptidoglycan component present in complete Freund’s
adjuvant,6 is the cognate ligand of the cytosolic NLR, NOD2.
Triggering of NOD2 ultimately results in activation of MAPK
and NFκB.7 Recently, we have studied the functionality of
chemically well-defined NOD2-ligand MDP upon conjugation
to synthetic long peptides (SLPs) and found that MDP retains
its agonistic activity upon conjugation,8 while the processing of
SLPs by dendritic cells was not hampered by conjugation of
MDP. Addition of a lipid side chain to MDP strongly
enhanced its functionality as a DC- and macrophage-maturing
agent, most likely explained by an enhanced uptake and
subsequent higher abundance in the cytosol where the NOD2
receptor is located.9−11
Depending on the different input of signals and expression
levels of receptors by an APC, the response of the APC will
vary accordingly and may result in either a predominant Th1-,
Th2-, or Th17-type response or an anti-inflammatory
response.12,13 Simultaneous triggering of different PRRs, such
as combined TLR- and NLR-triggering, can induce synergistic
effects. The first clues of this synergism derived from studies
published in 1979 and 1987 in which guinea pigs experienced
an enhanced endotoxic shock after inoculation with MDP and
other bacterial cell-wall derived substances.14 Increased
lethality and anaphylactoid reactions were also observed in
mice treated with LPS and MDP.15 In the past decade, several
groups have shown that a combination of NLR and TLR
triggering synergistically enhances the secretion of pro-
inflammatory cytokines by various cell types.16−21 A few
groups have specifically described the effects of combined
triggering of NOD2 and TLR2, inducing synergistic cytokine
release by various cell types.22−30 The activation of dendritic
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cells (DCs), which play a pivotal role in the onset of adaptive
immunity, can also be modulated by combined triggering of
NOD2 and TLR, which synergistically enhances the secretion
of inflammatory cytokines such as IL-12p70 and IFNγ.31
In the present study, we exploited the SLP platform to
generate conjugates of both Pam3CSK4 and MDP conjugated
to an SLP as a manner to modulate vaccine-induced innate and
adaptive responses. Here we designed and synthesized four
“dual conjugates” (conjugates 1−4, Figure 1). In Pam-SLP-
MDP conjugate 1, the peptide (SLP) is elongated at the N-
terminus with the TLR2-L, Pam3CSK4, while the side chain of
the C-terminal lysine is connected with the isoglutamine of
spacer containing MDP. Conversely, in MDP-SLP-Pam
conjugate 2 the isoglutamine of MDP is attached to the N-
terminus of the peptide epitope and Pam3CSK4 is bound to the
side chain of the C-terminal lysine of the antigenic peptide.
The Pam-MDP-SLP conjugate 3 and MDP-Pam-SLP con-
jugate 4 both contain a peptide that is provided with an
additional lysine at the N-terminus to allow conjugation of
both ligands on the same side of the conjugate via either the
side chain or the α-amino function of the introduced lysine.
For conjugate 3, the α-amino function is elongated with the
TLR2-L while the NOD2-L is connected to the side chain of
lysine. In comparison with conjugate 3, the linkages of the
ligands with the epitope in conjugate 4 are reversed. We
demonstrate that stimulation of human DCs by MDP-SLP-
Pam 2 constructs leads to synergistic cytokine and chemokine
release. In addition, we observe that murine T cells are induced
to produce more IFNγ and IL-2 upon exposure to DCs pulsed
with a MDP-SLP-Pam construct.
■ RESULTS
Synthesis of “Dual Conjugates” Containing Both
NOD-L and TLR2-L Connected to Synthetic Long
Peptide (SLP). The syntheses of conjugates 1−4 were largely
carried out with an automated peptide synthesizer, using
Fmoc-chemistry, the condensing agent HCTU and Tentagel-S-
RAM as solid support. Commercially available protected
amino acids and palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-
propyl)-OH were used (Scheme 1). The syntheses of bis-
conjugates 1−4 are depicted in Scheme 1 and require the
availability of MurNAc derivative 8, the preparation of which
has been described previously.8,9
The syntheses of bis-conjugates Pam-SLP-MDP 1 and
MDP-SLP-Pam 2 started with solid phase peptide synthesis
(SPPS) of resin bound peptide 5, having a C-terminal lysine
equipped with the orthogonal and acid labile monomethoxy-
trityl (Mmt) protective group allowing C-terminal extensions
at a later stage of the synthesis. To obtain conjugate 1, TLR2-L
Pam3CSK4 was attached to the N-terminus by elongation of
peptide 5 with the SKKKK motive using a standard SPPS
cycle, followed by a manual coupling with palmitoyl-Cys((RS)-
2,3-di(palmitoyloxy)-propyl)-OH under influence of PyBOP
and DiPEA resulting in immobilized peptide 6. Subsequently,
Figure 1. Dual conjugates (1−4) of four distinct structural types synthesized and investigated in this study. For the structures of the control
constructs, see Supporting Information (SI) Figure S1.
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immobilized peptide 6 was treated with a solution of 3% TFA
in DCM to selectively remove the Mmt protective group at the
side chain of the C-terminal lysine. To install the NOD2-L at
this position, the free amine was consecutively elongated with
Fmoc-isoglutamine, Fmoc-Ala-OH, and MurNAc derivative 8.
The coupling of 8 was executed twice using HATU instead of
HCTU as condensing agent. Conjugate 1 was simultaneously
deprotected and cleaved from the resin with a cocktail of 95%
TFA, 2.5% TIS, and 2.5% H2O for 60 min. The conjugate was
precipitated with diethyl ether and purified by RP-HPLC
yielding 2.5 mg Pam-SLP-MDP conjugate 1 in 2% overall
yield.
To synthesize dual conjugate 2, the NOD2-L was appended
at the N-terminus of immobilized 5 by the above-described
elongation with Fmoc-isoglutamine, Fmoc-Ala-OH, and
MurNAc 8. Next, the Mmt protective group at the side
chain of the C-terminal lysine was selectively removed and the
released amino group was extended with Pam3CSK4 by the
same sequence of reactions as described for conjugate 1. The
thus obtained immobilized 2 was cleaved from the solid
support, deprotected, and purified using the conditions as
described for conjugate 1 to give 0.94 mg MDP-SLP-Pam
conjugate 2 in 1% overall yield. The routes of synthesis to
conjugates Pam-MDP-SLP 3 and MDP-Pam-SLP conjugate 4
have the immobilized peptide 7, prepared by standard Fmoc
SPPS, in common. The side chain of the N-terminal lysine in 7
is protected with the orthogonal Mmt protective group,
permitting the successive addition of the TLR2 and NOD2
ligands. The sequence of reactions to install both the TLR2-L
and NOD2-L in 3 and 4 was adopted from the synthesis of
conjugate 1. To obtain 3, Pam3CSK4 was added to the free α-
amine of 7, followed by selective removal of the Mmt and
appendage of NOD2-L at the side chain of lysine. To obtain
conjugate 4, NOD2-L was added to the free α-amine of 7,
followed by selective removal of the Mmt and attachment of
Pam3CSK4 at the side chain of lysine. Acid treatment of the
immobilized and protected precursors of 3 and 4 led, after
precipitation and purification, to target Pam-MDP-SLP
conjugate 3 and MDP-Pam-SLP conjugate 4, both in 1%
overall yield. The relatively low overall yields obtained for the
syntheses of conjugates 1−4 can be explained by the
concurrent hydrolysis of the azidopropyl group at the anomeric
center of glucosamine of the NOD2-L.8 The hydrolyzed side
product hampered the final purification because of a small
difference in retention time between the target conjugates 1−4
and their corresponding side products.
MDP-SLP-Pam Conjugate Induces Strongest NOD2-
Triggering and Ensures Most Efficient Peptide Process-
ing. Since we aimed to improve antigenic peptide-based T-cell
vaccines by combining multiple PRR-triggers in one synthetic
molecule, a number of assays were performed to assess the
antigenicity of PRR-peptide conjugates that contain MDP,
Pam3CysSK4 (Pam), and SLP in a 1:1:1 stoichiometry.
Constructs consisting of either MDP or Pam conjugated to
SLP (SI Figure 1) were used as control compounds. All
conjugates (Figure 1) were based on an ovalbumin (OVA)-
derived SLP, harboring the Kb-restricted CTL-epitope
SIINFEKL. To identify the most optimal dual conjugate,
murine DCs were incubated overnight with the indicated
constructs (Figure 2A,B,C), after which the concentration of
IL-12p40 in the supernatant was determined as a measure of
DC activation (Figure 2A,B). The Pam-MDP-SLP, MDP-Pam-
SLP, Pam-SLP-MDP, and MDP-SLP-Pam conjugates all
showed strong induction of IL-12p40 induction by DCs
(Figure 2A,B). MDP-SLP-Pam conjugate was most efficiently
processed as shown by the activation of the SIINFEKL-specific
T cell hybridoma (B3Z) after coculture with murine DCs
loaded overnight with the indicated constructs (Figure 2C).
The same conjugate also showed the strongest activation of
human NOD2-transfected HEK293 cells after overnight
stimulation (Figure 2D). Therefore, the MDP-SLP-Pam
conjugate was selected as the most optimal construct and
used in the subsequent experiments.
Synthetic Conjugates Composed of MDP, Pam3CSK4,
and SLP Retain TLR2 and NOD2-Triggering Capacity.
Confirming findings reported earlier in the literature, mixing of
synthetic TLR2-L Pam3CSK4 and NOD2-L MDP induced
synergistic activation of human monocyte-derived DC
(moDC), as measured by the production of IL-12p40 (SI
Figure S2A). Addition of MDP to various concentrations of
Pam3CSK4 (Pam) led to a synergistic enhancement of IL-
12p40 secretion by these DCs. This synergism was not
observed in the expression of activation marker CD86 and
HLA-DR on the cell surface of DCs (SI Figure S2B).
To analyze whether the conjugates SLP-Pam and MDP-SLP
have retained their ability to trigger TLR2 and NOD2,
respectively, HEK293 cells transfected with either human
TLR2 (Figure 3A) or NOD2 (Figure 3B) were stimulated for
24 h with the conjugates described above, or with the single-
ligand containing conjugates as controls. Both Pam and MDP
can trigger their cognate receptor after conjugation to an SLP,
as measured by secretion of IL-8 in the supernatant. However,
TLR2-triggering was not enhanced by the dual conjugate
MDP-SLP-Pam (Figure 3A). By contrast, the NOD2-
expressing HEK293 cells show a clearly enhanced activation
by the MDP-SLP-Pam construct as compared with their
respective controls (Figure 3B). This is likely explained by
enhanced cell entry and increased cytosolic presence of the
Scheme 1. Synthesis of the Dual Conjugates 1−4a
aReaction conditions: (a) Fmoc SPPS cycle for SK4; (b) 20%
piperidine, NMP; (c) palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-prop-
yl)-OH, PyBOP, DiPEA; (d) 3% TFA, DCM; (e) Fmoc SPPS cycle
Fmoc-Ala-iGlu(NH2)-OH; ( f) 8, HATU, DiPEA, NMP; (g) 95%
TFA, 2.5% TIS, 2.5% H2O; (h) RP-HPLC, yield conjugates: (1) 2.5
mg, 2%, (2) 0.94 mg, 1%, (3) 1.2 mg, 1%, (4) 1.5 mg, 1%.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.9b00087
Bioconjugate Chem. 2019, 30, 1150−1161
1152
MDP-SLP-Pam conjugate because of the lipidated nature of
the constructs, as we have shown before.9 As a control, wild-
type nontransfected HEK293 cells were stimulated identically,
which did not lead to IL-8 production (SI Figure S3).
Together, these data show retained bioactivity of both TLR2-
and NOD2-ligands upon N- or C-terminal conjugation to
synthetic peptides.
Activation of Human DCs and PBMC by MDP-SLP-
Pam Constructs Leads to Enhanced Cytokine Produc-
tion. The combined triggering of receptors from different
Figure 2. MDP-SLP-Pam conjugate optimally induces activation of DCs, NOD2-triggering, and peptide processing. (A,B) Concentration of IL-
12p40 detected in the supernatant of murine DCs stimulated for 24 h with the indicated constructs. (C) Activation of T cell hybridoma B3Z
recognizing the processed SIINFEKL CTL epitope embedded in the conjugated SLPOVA, after overnight coculture with murine DCs previously
loaded overnight with indicated constructs. Activation determined by colorimetric change after CPRG enzymatic conversion, OD measured at 590
nm. (D) hNOD2-HEK293 cell activation as determined by IL-8 production measured in the supernatant of cells incubated overnight with the
indicated constructs. Depicted results are representative for 4 experiments conducted similarly with similar outcome. Significance determined by
one-way ANOVA and Bonferroni post-hoc test. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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Figure 3. Pam3CSK4 and MDP retain their ability to trigger their respective receptors upon conjugation to an SLP. (A) Detected concentration of
IL-8 as a measure of receptor-mediated activation of HEK293 cells transfected with hTLR2 (A) or hNOD2 (B), after stimulation with the indicated
titrated constructs containing an OVA-derived SLP. Significance determined by one-way ANOVA and Bonferroni posthoc test. **** p < 0.0001.
Figure 4. Cytokine and chemokine secretion profiles of human moDCs after stimulation with MDP-SLP-Pam constructs. (A) Concentration of IL-
12p40 in supernatant of human moDCs incubated overnight with indicated constructs containing an OVA-derived SLP. (B) Cytokines and
chemokines measured by Luminex in supernatants of moDCs stimulated with indicated MDP-SLP-Pam constructs. Representative results from 2
independently performed measurements. Significance determined by one-way ANOVA and Bonferroni posthoc test. * p < 0.05, **** p < 0.0001.
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PRR-families may skew the cytokine secretion profile of DCs.
Therefore, the supernatant of human moDCs stimulated with
the MDP-SLP-Pam construct and controls was analyzed using
ELISA (Figure 4A) and Luminex (Figure 4B) to quantify the
amounts of secreted IL-12p40, IL-6, IL-8, IFNγ, TNFα, MCP-
1, and CCL4. Stimulation with the MDP-SLP conjugate did
not induce secretion of any of the measured cytokines. In
contrast, Pam conjugated to SLP (SLP-Pam) induced all
measured cytokines. Although addition of free MDP to the
SLP-Pam constructs did not enhance the effects induced by
SLP-Pam alone, the dual MDP-SLP-Pam constructs strongly
increased the expression of all cytokines. This is most likely
explained by enhanced cellular uptake of the conjugated MDP
upon conjugation to a lipid moiety, i.e., Pam. The levels of
secreted IL-10 and IL-12p70 were also determined, which
showed a similar trend as the other cytokines that were
enhanced. However, the concentrations of the latter cytokines
were all below 10 pg/mL and therefore not included in Figure
4. Overall, the dual conjugation of both Pam and MDP to an
SLP induces a predominant inflammatory and Th1-associated
immune response.
Murine DC Maturation Enhanced by Dual MDP-SLP-
Pam Constructs. Murine assays provide a way to study the
impact of the dual-conjugated SLPs on T cell priming. In
Figure 5A, a murine DC cell line was stimulated with the
MDP-SLP-Pam conjugate and controls for 24 h, after which
the concentration of IL-12p40 was measured in the super-
natant. Similar to what was observed for human DCs, murine
DCs also produced significantly more IL-12p40 in response to
stimulation with the MDP-SLP-Pam construct, while the mix
of free MDP and SLP-Pam conjugate did not show synergy.
Figure 5B shows maturation of murine bone marrow-derived
DCs (BMDC), which are either of wild-type C57BL/6 origin
or of a TLR2-deficient mutant on a C57BL/6 background.
Maturation of BMDCs is clearly dependent on TLR2-
expression, as maturation of the TLR2−/− BMDCs was lost
or diminished after stimulation with any of the conjugates.
Although the conjugation of MDP to these constructs did not
enhance IL-12p40 production of the wild-type BMDCs, we did
observe partial TLR2−/− BMDC activation after stimulation
with the MDP-SLP-Pam conjugate (Figure 5B). This was also
observed in the expression of CD40 and CD86 by TLR2−/−
BMDC (SI Figure S4A). As a functionality control, the
TLR2−/− BMDC could be adequately activated by stimulation
with TLR9-L CpG to a similar extent as the WT BMDCs (SI
Figure S4B).
DCs Loaded with MDP-SLP-Pam Construct Induce
Enhanced CTL Priming. CD8+ T cells derived from the
transgenic mouse strain OT1 all recognize the SIINFEKL CTL
epitope of OVA. After CD8+ T cell enrichment of OT1
Figure 5. (A) Activation of murine DC cell line D1 as determined by measurement of secreted IL-12p40 in the supernatant after 16 h stimulation
with MDP-SLP-Pam construct. (B) Activation of BMDCs derived and cultured from bone marrow from naiv̈e WT or TLR2−/− C57BL/6 mice,
after 16 h stimulation with MDP-SLP-Pam constructs and controls. All experiments were repeated at least twice resulting in a similar outcome.
Significance in (A) determined by one-way ANOVA and Bonferroni posthoc test. Significance in (B) determined by unpaired t test for each
construct. **** p < 0.0001.
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splenocytes and lymph node-derived cells, the OT1 CD8+ T
cells were added to washed murine DCs that had been
incubated overnight with the MDP-SLP-Pam construct or
controls. Subsequent intracellular cytokine staining revealed a
strongly enhanced synthesis of IFNγ, IL-2, and TNFα by the
OT1 exposed to DCs incubated with the MDP-SLP-Pam
construct as compared with the control constructs (Figure
6A,B,C,D). In accordance with the increased number of CD8+
T cells with intracellular cytokine production, the levels of
secreted IFNγ and IL-2 detected in the supernatant were also
Figure 6. Enhanced specific T cell activation via murine DCs loaded with MDP-SLP-Pam construct. Activation of enriched transgenic OT1 CD8+
T cells cocultured for 48 h with murine D1 DCs that had been stimulated overnight with indicated constructs containing an OVA-derived SLP.
OT1 CD8+ T cell activation determined by flow cytometric measurement of frequency of T cells with accumulated (A) IFNγ, (B) IL-2, (C) TNFα,
and (D) both IFNγ and IL-2. Data from the same experiment indicating the concentration of (E) IFNγ and (F) IL-2 in the supernatant of
cocultures as determined by ELISA. Experiment was repeated once resulting in a similar outcome. Significance in (E) determined by one-way
ANOVA and Bonferroni posthoc test. * p < 0.05.
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strongly enhanced after coculture of OT1 T cells with DCs
loaded with the MDP-SLP-Pam construct (Figure 6E,F).
■ DISCUSSION
In the present study, we have characterized the properties of a
dual synthetic peptide conjugate incorporating ligands for two
different PRR families, e.g., NOD2-L MDP and TLR2-L
Pam3CSK4. This first-of-a-kind synthetically designed con-
jugate vaccine induces an immune response with a pro-
inflammatory and Th1-type biased immune signature which is
of importance in the treatment of, e.g., cancer or (chronic)
virus infections.
From an evolutionary point of view, cooperative signaling
following from combined triggering of NOD2 and TLR2
makes sense as ligands for both receptors are derived from
bacterial structures. The synergism arising after stimulation of
both TLR2 and NOD2 has been studied extensively and
mainly focuses on enhanced levels of cytokine secretion by
various (mostly myeloid) cell types.22−30 Different mecha-
nisms for the synergy have been proposed: (1) MDP-induced
upregulation of MyD88, lowering the threshold for subsequent
TLR triggering,22,24 and (2) converging signaling cascades
downstream of both TLR and NOD2 triggering.32 The latter
mechanism involves the ubiquitination of NFκB essential
modifier (NEMO) which is an essential step preceding NFκB
activation. NEMO ubiquitination is partially mediated by
TRAF6, an E3 ubiquitination ligase that is part of both TLR2
and NOD2 signaling cascades.19,32 Also, the CARD-domain
containing Rip2 kinase (Rip2K), which binds activated NOD2,
contributes to activation of TRAF6-mediated MAP kinase
pathways downstream of TLR2 triggering.33
Stimulation of human DCs by the MDP-SLP-Pam
constructs led to synergistically enhanced levels of secreted
cytokines (Figure 4) with a predominant pro-inflammatory
signature (IL-6, IFNγ, TNFα) and chemokines (IL-8, MCP-1,
and CCL4). CCL4 is known to recruit Th1-type naiv̈e T cells,
immature DCs, macrophages, and monocytes34 while MCP-1
recruits memory T cells, monocytes, and macrophages, in
addition to described pro- and antitumor effects.35 The
supernatant concentrations of IL-10 and IL-12p70 were
below detection limits after stimulation with the MDP-SLP-
Pam construct. The lack of IL-12p70 production was also
described in a study by Tada et al., in which the authors
observe synergism in IL-12p70 production by human DCs
stimulated with MDP and several TLR-ligands (TLR3-L,
TLR4-L, and TLR9-L) but not between MDP and TLR2-L.31
Still, the MDP-SLP-Pam construct strongly tips the balance
toward a pro-inflammatory and Th1-oriented cytokine profile
when stimulating human DCs.
In mice, we observe efficient maturation of murine WT
BMDCs by both the SLP-Pam and MDP-SLP-Pam constructs
with no additive effect of the conjugated MDP. Murine
BMDCs have a low activation threshold which may explain
why the additive effect of MDP-conjugation is not observed.
Although we did not determine the expression of NOD2 in
these BMDCs, Yang et al. show that C57BL/6-derived
CD11c+ splenic DCs do express NOD2.36 Also, the
observation that MDP-SLP-Pam induces a partial maturation
of the TLR2−/− BMDCs suggests that NOD2 is expressed in
these cells (Figure 3C).
Strober and colleagues have previously shown that excessive
Th1 responses can arise from mutations in the gene encoding
for NOD2 (CARD15), which are frequently observed in
Crohn’s disease and inflammatory bowel disease (IBD)
patients.36−39 The authors claim that TLR2-induced activation
of NFκB is inhibited by NOD2 activation, although others
have come up with alternative or contradictory findings.40−42
The molar concentrations of MDP used in the Strober studies
are, however, roughly 10-fold higher than the molar
concentrations of Pam3CSK4. By generating constructs in
which one MDP-molecule and one Pam3CSK4-molecule are
coupled to one SLP in our study, we probably prevent MDP-
mediated overstimulation of APCs such as observed by Strober
et al. Borm and colleagues specifically focused on dosage
effects of MDP and found that TLR2-primed monocytes
upregulated their cytokine secretion in response to low doses
of MDP, whereas a high dose of MDP downregulated the
responses.43 Moreover, in our hands stimulation of moDCs
using 80-fold higher concentrations of free MDP (20 μM) than
free Pam3CSK4 (0.25 μM) also led to significantly enhanced
levels of IL-12p40 production (data not shown).
Dendritic cells stimulated with the MDP-SLP-Pam construct
improved specific CD8+ T cell activation in vitro (Figure 6).
■ CONCLUSION
In conclusion we have described for the first time the synthesis
and in vitro evaluation of conjugates consisting of ligands for
both NOD2 and TLR2-L attached to an antigenic peptide with
a class-I epitope sequence embedded. The data on the
immunogenicity of the most active conjugate MDP-SLP-Pam
indicate that such a construct not only improves activation of
the antigen specific T-cells as compared to monoconjugates
but also predominantly stimulates a proinflammatory and Th1-
type response. This means that the MDP-SLP-Pam constructs
have the potential to be applied as a vaccine against, e.g.,
(chronic) virus infections and tumors. In both cases, Th1-type
responses characterized by specific CTL activation, adequate
cytotoxicity and production of cytokines such as IFNγ, TNFα,
and IL-2 are required for eradication of affected cells. This sets
the stage to analyze whether MDP-SLP-Pam constructs also
induce functional T cell responses in vivo.
■ EXPERIMENTAL PROCEDURES
Synthesis of MDP-SLP-Pam Constructs. All reagents
and solvents used in the solid phase peptide synthesis were
purchased from Bachem and Biosolve and used as received.
Palmitoyl-Cys((RS)-2,3-di(palimitoyloxy)-propyl)-OH was
purchased from Bachem, Fmoc-amino acids from Novabio-
chem. Free MDP-OH (3S), MDP-SLP (1S) conjugates (SI
Figure 1) were prepared as described8 as well as Pam3CSK4
(4S).44 Tentagel based resins were ordered from Rapp
Polymere. Light petroleum ether with a boiling range of 40−
60 °C was used. All other solvents used under anhydrous
conditions were stored over 4 Å molecular sieves except for
methanol, which was stored over 3 Å molecular sieves.
Solvents used for work-up and silica gel column chromatog-
raphy were of technical grade and distilled before use. All other
solvents were used without further purification. Reactions were
monitored by TLC analysis or LC/MS analysis. LC/MS was
conducted on a JASCO system using an Alltima C18 analytical
column (4.6 × 50 mm, 5 μm particle size, flow 1.0 mL/min),
Alltima CN analytical column (4.6 × 50 mm, 3 μm particle
size, flow 1.0 mL/min), or a Alltima C4 analytical column (4.6
× 50 mm, 5 μm particle size, flow 1.0 mL/min). Absorbance
was measured at 214 and 256 nm. Solvent system: A: 100%
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water, B: 100% MeCN, C: 1% aq. TFA. Gradients of MeCN in
10% C were applied over 15 min unless stated otherwise.
Purifications were conducted on the Gilson GX-281
preparative RP-HPLC system, supplied with a semi preparative
Alltima CN column (10 × 250 mm, 5 μm particle size, flow 5.0
mL/min) or semi preparative Alltima C4 column (10 × 250, 5
μm particle size, flow 5.0 mL/min). Solvent system: A: 0.1%
aq. TFA and B: MeCN. Gradients of 10−90% MeCN were
applied over 3 CV over 15 min unless stated otherwise. The
UV absorption was measured at 214 and 256 nm. High
resolution mass spectra were recorded by direct injection (2
μL of a 2 μM solution in H2O/MeCN; 50/50: v/v and 0.1%
formic acid) on a mass spectrometer Thermo Finnigan LTQ
Orbitrap equipped with an electrospray ion source in positive
mode (source voltage 3.5 kV, sheath gas flow 10, capillary
temperature 523 K) with resolution R = 60000 at m/z 400
(mass range m/z = 150−2000) and dioctyl phthalate (m/z =
391.28428) as lock mass. Optical rotations were measured on a
Propol automatic polarimeter (sodium D-line, λ = 589 nm).
Specific rotations [α]D are given in degrees per centimeter and
the concentration c is given in mg/mL in the specific solvent.
Maturation and B3Z presentation results were analyzed with
Graphpad Prism version 5.01 for Windows, GraphPad
Software, San Diego, California, USA. IR spectra were
recorded on a PerkinElmer Paragon 1000 FT−IR Spectrom-
eter.
General Procedure for Automated Solid-Phase Syn-
thesis. The solid-phase peptide synthesis was performed on a
50 μmol or 25 μmol scale according to established methods8,45
on an ABI 433A (Applied Biosystems) automated instrument
applying Fmoc based protocol starting from Tentagel-S-RAM
resin (loading 0.23 mmol/g) or loaded with described peptide.
The synthesis was continued with Fmoc-amino acids specific
for each peptide. The consecutive steps performed in each
cycle for HCTU chemistry on 50 μmol scale:
1. Deprotection of the Fmoc-group with 20% piperidine in
NMP for 15 min. 2. NMP wash. 3. Coupling of the appropriate
amino acid using a 5-fold excess. Generally, the Fmoc amino
acid (0.25 mmol) was dissolved in 0.25 M HCTU in NMP (1
mL); the resulting solution was transferred to the reaction
vessel followed by 0.5 mL of 1.0 M DiPEA in NMP to initiate
the coupling. The reaction vessel was then shaken for 30 min.
4. NMP wash. 5. Capping with 0.5 M acetic anhydride in NMP
in the presence of 0.5 mmol DiPEA. 6. NMP wash. 7. DCM
wash.
Aliquots of resin of the obtained sequences were checked on
an analytical Alltima C18 column (4.6 × 50 mm, 5 μm particle
size, flow 1.0 mL/min). The Fmoc amino acids applied in the
synthesis were as follows: Fmoc-Ala-OH, Fmoc-Asn(Trt)-OH,
Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu-
(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH,
Fmoc-Lys(Boc)-OH, Fmoc-Lys(Mmt)-OH, Fmoc-Phe-OH,
Fmoc-Ser(tBu)-OH, and Fmoc-Val-OH.
General Procedure Coupling Palmitoyl-Cys((RS)-2,3-
di(palmitoyloxy)-propyl)-OH. Swollen 25 μmol resin loaded
with peptide as mentioned was treated with a stock solution of
palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-OH (0.18
M) and PyBOP (0.22 M) in DCM: NMP (2:1, 1 mL). The
resulting mixture was treated with 25 μmol DiPEA at t = 0 and
t = 15 min. The resulting suspension was reacted by shaking
for 18 h followed by NMP and DCM wash.
General Procedure for Cleavage from the Resin,
Deprotection, and Purification. For the cleavage and
deprotection the immobilized conjugates were treated with a
cleavage cocktail of 95% TFA, 2.5% TIS, and 2.5% H2O for 60
min. To purify the conjugates, all the precipitates were
dissolved in a 1:1:1 mixture of MeCN, tBuOH, and H2O and
sonicated for 15 min. The mixtures were centrifuged and
filtered before injection on the RP-HPLC. The cleavage from
the resin, deprotection, and purification by RP-HPLC were
performed as previously reported.8 All isolated conjugates were









Tentagel-S-Ram was elongated with Ser(tBu)-Lys(Boc)-Lys-
(Boc)-Lys(Boc)-Lys(Boc) with standard HCTU/Fmoc chem-
istry concluding in final Fmoc removal with a solution of 20%
piperidine in NMP (4 × 3 min). The resin was treated with
Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-OH in the
presence of PyBOP and DiPEA in NMP: DCM (1 mL) for 18
h. The resin was washed (NMP, DCM) and treated with a
solution of 3% TFA in DCM. The resin was elongated with
standard Fmoc/HCTU chemistry for Fmoc-i-D-Gln(OH)-
NH2, Fmoc-Ala-OH. The synthesis was completed with a
double coupling of a 2-fold excess of compound 8 preactivated
with HATU and DiPEA. To conclude, the resin was treated
with a standard cleavage cocktail for 60 min and precipitated
with Et2O. After purification by RP-HPLC title compound 1
was obtained in 2.52 mg (0.55 μmol, 2.2%); LC/MS: Rt = 6.99
min (C4 Alltima, 50−90% MeCN, 15 min run); ESI-MS: m/z
1533.0 [M+3H]3+; 2298.6 [M+2H]2+; HRMS Calcd for
[C215H374N46O60S1 + H]




Lys-Lys-Lys-Lys)-NH2 (2). 2 (MDP-SLP-Pam). Twenty-five
μmol of crude H-Asp(OtBu)-Glu(OtBu)-Val-Ser(tBu)-Gly-
Leu-Glu(OtBu)-Gln(Trt)-Leu-Glu(OtBu)-Ser(tBu)-Ile-Ile-
Asn(Trt)-Phe-Glu-Lys(Boc)-Leu-Ala-Ala-Ala-Ala-Ala-Lys-
(Mmt)-Tentagel-S-Ram was elongated with standard Fmoc/
HCTU chemistry for Fmoc i-D-Gln(OH)-NH2, Fmoc-Ala-OH.
The synthesis was completed with a double coupling using a 2-
fold excess of compound 8 (preactivated with HATU and
DiPEA). The resin was treated with a cleavage cocktail of 3%
TFA in DCM and was elongated with Fmoc-Ser(tBu)-
Lys(Boc)-Lys(Boc)-Lys(Boc)-Lys(Boc). The resin was treated
with a solution of 20% piperidine in NMP (4 × 3 min). The
synthesis was proceeded by treating the resin with a solution of
Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-OH in
NMP: DCM (1:1) in the presence of PyBOP and DiPEA
for 18 h. The resin was washed (NMP, DCM) and treated with
the previously described peptide cleavage and deprotection
conditions for 60 min. Purification of the precipitated peptide
by RP-HPLC resulted compound 2 (0.94 mg, 0.20 μmol,
0.8%); LC/MS: Rt = 7.06 min (C4 Alltima, 50−90% MeCN,
15 min run); ESI-MS: m/z 1533.1 [M+3H]3+; HRMS Calcd
for [C215H374N46O60S1 + H]
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Ala-Ala-Ala-Ala-Lys-NH2 (3). 3 (Pam-MDP-SLP). Twenty-five
μmol of crude H-Asp(OtBu)-Glu(OtBu)-Val-Ser(tBu)-Gly-
Leu-Glu(OtBu)-Gln(Trt)-Leu-Glu(OtBu)-Ser(tBu)-Ile-Ile-
Asn(Trt)-Phe-Glu-Lys(Boc)-Leu-Ala-Ala-Ala-Ala-Ala-Lys-
(Boc)-Tentagel-S-Ram was elongated with Ser(tBu)-Lys(Boc)-
Lys(Boc)-Lys(Boc)-Lys(Boc)-Lys(Mmt)-OH according to
described HCTU/Fmoc chemistry followed by a coupling of
Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-OH in the
presence of PyBOP and DiPEA. The resin was treated with a
cleavage cocktail of 3% TFA in DCM and was elongated with
standard Fmoc/HCTU chemistry for Fmoc i-D-Gln(OH)-NH2
and Fmoc-Ala-OH. The synthesis was completed with a
double coupling using a 2-fold excess of compound 8
preactivated with HATU and DiPEA. The resin was treated
with the previously described cleavage and deprotection
method for 60 min. Purification by RP-HPLC resulted in
compound 3. (1.2 mg, 0.25 μmol, 1.1%); LC/MS: Rt = 6.27
min (C4 Alltima, 50−90% MeCN, 15 min run); ESI-MS: m/z
1575.9 [M+3H]3+, 1182.3 [M+4H]4+; HRMS Calcd for
[C221H386N48O61S1 + H]




Ala-Ala-Ala-Ala-Ala-Lys-NH2 (4). 4 (MDP-Pam-SLP). Twenty-
five μmol of crude N-Asp(OtBu)-Glu(OtBu)-Val-Ser(tBu)-
Gly-Leu-Glu(OtBu)-Gln(Trt)-Leu-Glu(OtBu)-Ser(tBu)-Ile-
Ile-Asn(Trt)-Phe-Glu-Lys(Boc)-Leu-Ala-Ala-Ala-Ala-Ala-Lys-
(Boc)-Tentagel-S-Ram was elongated with standard Fmoc/
HCTU chemistry for Fmoc-Lys(Mmt)-OH, Fmoc-i-D-Gln-
(OH)-NH2, and Fmoc-Ala-OH. The resin was elongated with
a double coupling using a 2-fold excess of compound 8
preactivated with HATU and DiPEA. The resin was treated
with a cleavage cocktail of 3% TFA in DCM and the resin was
elongated with Fmoc-Ser(tBu)-Lys(Boc)-Lys(Boc)-Lys(Boc)-
Lys(Boc). The resin was treated with a solution of 20%
piperidine in NMP. The synthesis was continued by treating
the resin with a coupling of Palmitoyl-Cys((RS)-2,3-di-
(palmitoyloxy)-propyl)-OH in the presence of PyBOP and
DiPEA. After the wash steps (NMP, DCM) the resin was
treated with the previously described cleavage and depro-
tection cocktail for 60 min. Purification by RP-HPLC resulted
compound 4. (1.5 mg, 0.28 μmol, 1.1%); LC/MS: Rt = 6.55
min (C4 Alltima, 50−90% MeCN, 15 min run); ESI-MS: m/z
1575.8 [M+3H]3+; HRMS Calcd for [C221H386N48O61S1 +




(2S). 2S (SLP-Pam). Tentagel S RAM resin loaded with H-
Asp(OtBu)-Glu(OtBu)-Val-Ser(tBu)-Gly-Leu-Glu(OtBu)-Gln-
(Trt)-Leu-Glu(OtBu)-Ser(tBu)-Ile-Ile-Asn(Trt)-Phe-Glu-Lys-
(Boc)-Leu-Ala-Ala-Ala-Ala-Ala-Lys(Mmt) on 25 μmol was
treated 1 M Boc2O in NMP for 15 min followed by addition of
2 equiv of DiPEA and reacted for another hour. The resin was
washed with NMP and DCM. The resin was treated with a
cleavage cocktail of 3% TFA in DCM followed by a coupling
sequence to elongate the resin with Ser(tBu)-Lys(Boc)-
Lys(Boc)-Lys(Boc)-Lys(Boc). The resin was treated with a
solution of 20% piperidine in NMP (4 × 3 min). The resin was
treated with Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-prop-
yl)-OH in the presence of PyBOP and DiPEA in a NMP:DCM
mixture (1:1) for 18 h. The resin was washed (NMP, DCM)
and treated with standard cleavage and deprotection
conditions. Purification by RP-HPLC yielded compound 2S.
(0.63 mg, 0.16 μmol, 0.62%); LC/MS: Rt = 6.93 min (C4
Alltima, 50−90% MeCN, 15 min run); ESI-MS: m/z 1347.1
[M+3H]3+, 1010.6 [M+4H]4+, 808.6 [M+4H]5+ HRMS Calcd
for [C193H339N39O50S + H]
3+ 1346.83932, found 1346.84366.
Cell Culture. Bone marrow derived cells (BMDC) are
isolated from WT and TLR2−/− C57BL/6 mice by flushing the
bone marrow with complete IMDM culture medium (Lonza),
containing 10% FCS (Greiner Bio-one), penicillin/streptomy-
cin (Gibco), L-glutamine (Gibco), and β-mercaptoethanol
(Sigma-Aldrich). After culturing for 7 days in complete IMDM
culture medium supplemented with 30% supernatant of R1
cultures, as described,44 BMDCs were fed with fresh medium
containing 30% R1 supernatant. BMDCs were used in
experiments on day 9 or 10. The D1 cell line is a growth
factor-dependent immature splenic DC cell line, derived from
C57Bl/6 (H-2b) mice. D1 cells were cultured as described.46
The B3Z hybridoma is cultured in complete IMDM medium
supplemented with 500 μg/mL hygromycin.47 The human
TLR2- and NOD2-receptor expressing HEK293 cells (In-
vivogen) were cultured in accordance with the manufacturer’s
protocol in complete IMDM culture medium supplemented
with 10 μg/mL blasticidin. Wild-type HEK293 control cells
were cultured in complete IMDM culture medium. Monocyte-
derived DCs (moDC) were generated from the CD14+
fraction of PBMC derived from healthy donors. PBMC were
isolated over a Ficoll gradient. The CD14+ fraction was
isolated from the PBMC using CD14 Microbeads (MACS;
Miltenyi). These cells were subsequently cultured in complete
RPMI1860 medium (Gibco) in the presence of 800 U/mL
GM-CSF and 500 U/mL IL-4 (both Peprotech) for 5 days.
In Vitro DC Activation Assay. Test compounds were
titrated in a 96-well plate (Corning) in complete IMDM
medium. Next, D1 cells, wild-type BMDC or TLR2−/− BMDC,
or moDCs were added to the 96-well plates containing the test
compound titrations, using approximately 50 000 cells per well
(D1 or moDC) or 20 000 cells per well (BMDC). After 24 h of
incubation at 37 °C, supernatant was taken from the wells for
ELISA analysis (BioLegend) in which the amount of produced
IL-12p40 was measured. After 48 h of incubation at 37 °C, the
cells were stained for CD40, CD86, and/or MHC class II
(eBioscience) for FACS analysis.
NOD2- and TLR2-Transfected HEK293 Cell Activation.
Test compounds were titrated in a 96-wells plate. Approx-
imately 20,000 NOD2-HEK293 or TLR2-HEK293 cells were
added per well. After 24 h of incubation at 37 °C, the
supernatant was taken from all wells. The amount of IL-8
produced by the NOD2- or TLR2-HEK293 cells, a measure
for HEK293 cell activation, was determined using ELISA
(Sanquin).
Luminex. Supernatants collected from cell cultures
containing any of the described stimulatory compounds were
analyzed for the presence of cytokines and chemokines as
specified in Figure 3. Luminex technology was applied to
measure different analytes in the same sample using a custom
multiplex kit (Biorad).
In Vitro T Cell Activation. Naive transgenic OT1 mice
were sacrificed at 6−8 weeks of age and spleen and lymph
nodes were harvested. After bringing spleen and lymph node
cells in suspension, an enrichment for CD8+ T cells was
performed by a CD8+ T cell enrichment kit (BD). A high
purity (<95%) suspension of OT1 CD8+ T cells was obtained,
that are specific for the ovalbumin-derived CTL epitope
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SIINFEKL. After loading murine D1 DCs with different
constructs overnight and subsequent washing of these DCs, the
OT1 CD8+ T cells were cocultured for 48 h with the loaded
DCs, before addition of 10 μg/mL Brefeldin A for 16 h. The
following day, intracellular cytokine staining was performed on




The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.bioconj-
chem.9b00087.
Drawing of the structures of control conjugates and free
TLR-ligands, supplementary data on DC-stimulation,
data on the activation of nontransfected HEK-cells, LC-
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